By Joseph Burns, from the Volume XXVI No. 11 – August 12, 2019 issue
IT’S OFFICIAL! A YEAR-LONG COLLABORATION involving a health insurer, a clinical laboratory, and an analytics company showed that insurers and physicians can use clinically-actionable intelligence developed from medical lab test data to improve patient outcomes.
This important accomplishment in patient care comes with another significant milestone: The health insurer is paying the lab outside of the
By Joseph Burns, from the Volume XXV No. 12 – August 20, 2018 issue
CEO SUMMARY: Fast-growing ProMedica Health System of Toledo, Ohio, agreed to a laboratory joint venture with Sonic Healthcare USA. As lab budgets and prices for lab tests are squeezed downward, ProMedica sees opportunity to add volume to this new core lab facility to improve efficiency and reduce costs per test. At the same time, it
By Joseph Burns, from the Volume XXV No. 11 – July 30, 2018 issue
FOR ALL CLINICAL LABORATORIES AND PATHOLOGISTS, the hacking problems Laboratory Corporation of America experienced earlier this month are a reminder that unwanted IT attacks are not a matter of if, but when. It is an accepted fact that labs and other medical providers are at higher risk of such attacks because computer hackers value patients’
By Robert Michel, from the Volume XXIV, No. 14 – October 9, 2017 issue
Sept. 22 was the day that an agreement to sell Miraca Life Sciences (MLS) of Irving, Texas, was announced. Miraca Holdings will sell the anatomic pathology lab company to Avista Capital Partners. As part of the transaction, a new holding company, called Symphony Buyer, will be formed and will own MLS. Miraca Holdings will be
By Joseph Burns, from the Volume XXIV, No. 10 – July 17, 2017 issue
CEO SUMMARY: In five months, Medicare officials will implement a new Part B clinical laboratory fee schedule based on private payer lab price data submitted by certain medical laboratories required to report that data. At this year’s Executive War College, the CEO of XIFIN, Inc., reported on her company’s analysis of the payer price data
By Robert Michel, from the Volume XXIII, No. 6 - May 2, 2016 issue
CEO SUMMARY: What happens when 100 lab experts interact with an audience of more than 850 lab administrators, pathologists, and IVD executives from across the United States and seven other nations? A consensus of sorts emerges and during this 2016 edition of the Executive War College on Lab and Pathology Management, that consensus was how:
By Joseph Burns, from the Volume XXIII No. 5 - April 11, 2016 issue
CEO SUMMARY: Two different business models of clinical laboratory consulting have now been brought together. Chi consultants have long focused on analytics and improving outreach performance, among other areas of lab performance. By contrast, Accumen’s business model is nontraditional and centers upon a shared-savings partnership with a hospital or health system. Executives at Accumen are betting that a combination of both types
By judeb
CEO SUMMARY: There is a new buyer for lab test data, creating an opportunity for labs to build a new revenue stream. Medivo, Inc., of New York, describes itself as a healthcare data analytics company whose mission is to unlock the power of lab data to improve health. It works with clinical labs and pathology groups to de-identify and integrate
By Joseph Burns, from the Volume XXII, NO. 18 - December 28, 2015 issue
CEO SUMMARY: There is a new buyer for lab test data, creating an opportunity for labs to build a new revenue stream. Medivo, Inc., of New York, describes itself as a healthcare data analytics company whose mission is to unlock the power of lab data to improve health. It works with clinical labs and pathology
By Robert Michel, from the Volume XXII NO. 16 - November 16, 2015 issue
MORE LAB CONSOLIDATION is happening in Connecticut. Last week, Quest Diagnostics Incorporated announced it will purchase the outreach laboratory business of Clinical Laboratory Partners. CLP is a division of Hartford HealthCare, a health system with five hospitals in Connecticut.
After regulatory review, the acquisition is expected to become final early next year. Terms were not disclosed.
CLP
